Interestingly, the magnitude of intratumoral CD8+ T-cell expansion induced by CD8-mIL2 was comparable with that observed for peripheral blood CD8+ T cells, despite the expected lower drug exposure in tumor compared with the periphery. This evidence concerns the gene CD8A and neoplasm.